



## When are we handed the baton?






Products come either through an internal R&D pipeline or M&A

Sometimes we have years to prepare or just months

Sometimes clinical trials are conducted in Canada, sometimes not



Creating a Canada Business Model to bring new innovative products to Canada



### Canada Business Model



### Patient pool

Total population 38,246,108

Prevalence 63.03cases /1m people

Diagnosis rate 100%percentage

Platelet <50x10^9/L 35%percentage

**Patient growth** 

YoY growth patients 2.20% percentage

2022 2023 2024 2025 2026 2027 2028
Relevant patient population <50x10^9/L 846 865 884 903 923 943 964

#### **Market Share**

<50x10^9/L

Starting year for revenue generation 2026 year

Starting year market share <50x10^9/L 10%percentage

Peak market share <50x10^9/L 45%percentage

Annual market share increase <50x10^9/L 7%percentage points

Loss of exuclusivity date 2031year

STRICTLY CONFIDENTIAL - FOR INTERNAL DISCUSSION PURPOSES ONLY



## **Canada Business Model**

- **NEXT PHASE** is inputting variables:
  - Price (PMPRB, CADTH, INESSS, pCPA, PLAs)
  - Timing through the system
  - Operating expenses to bring product to market
  - Manufacturing costs
  - Fees
  - Employee resources
  - Competitive landscape



# The Hurdles





Damien Warner Canadian Decathlon

Then it starts to get real

Health Canada Priority Review Standard Review NOC-C

CADTH INESSS

PMPRB HDAP

pCPA

**Provincial PLA** 

Private Payer Listings





Any one of these hurdles can trip you up **and** shut the whole thing down at any time

Health Canada Priority Review Standard Review NOC-C

CADTH INESSS

PMPRB HDAP

*pCPA* 

**Provincial PLA** 

Private Payer Listings



